Interleukin-33 variants, compositions and uses thereof
AssigneesSlate Bio, Inc., University of Virginia Patent Foundation
InventorsMichelle SOLTERO HIGGIN, Rahul SHARMA
Life of this patent
Estimating the term…
Abstract
The present invention provides, among other things, improved interleukin-33 (IL-33) variants engineered for increased manufacturability and activity, for example, mutated at one or more of N60, C116, C97, C121 or C148 relative to a truncated IL-33. The present invention also provides a multifunctional fusion protein comprising an IL-33 variant associated with an IL-2 polypeptide and optionally, a half-life extension moiety. The present invention further provides compositions and methods for proliferation and activity of ST2+ regulatory T cells, for prophylaxis and treatment of autoimmune disease.
Claims64
A recombinant human interleukin-33 (IL-33) variant comprising one, two, three, four or five amino acid substitutions at N60, C97, C116, C121, and C148, wherein the IL-33 has improved activity and/or manufacturability relative to wild-type IL-33.
A recombinant human interleukin-33 (IL-33) variant comprising an amino acid substitution at N60 and any one of C97, C116, C121 or C148.
A recombinant human interleukin-33 (IL-33) variant comprising an amino acid substitution C116F and an additional amino acid at any one of C97, C121 or C148.
A recombinant human interleukin-33 (IL-33) variant comprising at least one amino acid substitution selected from N60S, N60D, N60T, N60A, N60Q, N60E C97G, C97A, C97V, C116A, C116F, C116Y, C121A, C121S, C148A, C148G, C148S, C148Y or C148N.
The recombinant human IL-33 variant of any one of the preceding claims comprising the amino acid substitutions of C97G and C116F.
The recombinant human IL-33 variant of any one of the preceding claims, wherein the IL-33 is truncated.
The recombinant human IL-33 variant of any one of the preceding claims, wherein the polypeptide comprises the sequence of any one of SEQ ID NOs:
- 2-8, and SEQ ID NOs:
- 82-83.
A fusion protein comprising IL-33 of any one of the preceding claims.
The fusion protein of any one of the preceding claims, further comprising a half-life extension moiety.
A multifunctional fusion protein comprising:
- an IL-2 polypeptide,
- an IL-33 polypeptide, and
- a half-life extension moiety,
- wherein the half-life extension moiety is located at the N-terminus or C-terminus of the fusion protein.
A multifunctional fusion protein comprising:
- an IL-2 polypeptide,
- an IL-33 polypeptide, and
- a half-life extension moiety,
- wherein the half-life extension moiety is not an Fc domain of IgG.
The multifunctional fusion protein of any one of the preceding claims, wherein the IL-33 polypeptide is a variant wherein the variant has improved activity and/or manufacturability relative to wild-type IL-33.
The multifunctional fusion protein of any one of the preceding claims, comprising one, two, three, four or five amino acid substitutions at N60, C97, C116, C121, and C148.
The multifunctional protein of any one of the preceding claims, comprising the amino acid substitutions of C97G and C116F.
The multifunctional fusion protein of any one of the preceding claims, wherein the IL-33 is truncated.
The multifunctional fusion protein of any one of the preceding claims, wherein the IL-33 polypeptide comprises the sequence of any one of SEQ ID NO:
- 2-8, and SEQ ID NOs:
- 82-83.
The multifunctional fusion protein of any one of the preceding claims, wherein the IL-2 polypeptide is a variant IL-2.
The multifunctional fusion protein of any one of the preceding claims, wherein the IL-2 polypeptide comprises N88R, N88S, C125S, V69A or Q74P.
The multifunctional fusion protein of any one of the preceding claims, wherein the half-life extension moiety is selected from the group consisting of monomethoxy poly-ethylene glycol (PEG), albumin, transferrin, Fc domain of IgG, highly sialylated peptide, XTEN, V-P-G-x-G (ELP), proline-alanine-serine (PAS) polymer, homo amino acid polymer (HAP) and gelatin-like protein (GLK).
The multifunctional fusion protein of any one of the preceding claims, wherein the IL-2 and IL-33 polypeptides are 10 to 100 angstrom units (Å) apart.
The multifunctional fusion protein of any one of the preceding claims, wherein the multifunctional protein further comprises a linker.
The multifunctional fusion protein of any one of the preceding claims, further comprising a tag at the N-terminus or C-terminus.
The multifunctional fusion protein of any one of the preceding claims comprising the sequence of any one of SEQ ID NO:
- 58-79.
The multifunctional fusion protein of any one of the preceding claims, wherein the fusion protein is lyophilized.
A polynucleotide encoding the IL-33 polypeptide or the multifunctional fusion protein of any one of the preceding claims.
A pharmaceutical composition comprising the multifunctional fusion protein of any one of the preceding claims.
A method of treating an autoimmune disease, the method comprising administering to a subject in need thereof a therapeutically effective dose of a multifunctional fusion of an IL-2 polypeptide, an IL-33 polypeptide, and a half-life extension moiety, wherein the half-life extension moiety is located at the N-terminus or C-terminus of the fusion protein.
The method of any one of the preceding claims, wherein the administration stimulates proliferation and/or activation of immune cells.
The method of any one of the preceding claims, wherein the immune cells are ST2+ cells, Foxp3-ST2+ and Foxp3-ST2-Tr1 cells, Th3 cells, ILC2, macrophages, MDSCs, regulatory B cells, B1B cells, or tolerogenic dendritic cells.
The method of any one of the preceding claims, wherein the administration leads to coexpression of IL-2 and IL-33 in the same tissue.
The method of any one of the preceding claims, wherein IL-2 and IL-33 synergistically show increased potency and/or increased avidity relative to IL-2 or IL-33 alone.
The method of any one of the preceding claims, wherein administration increases local immune tolerance in a tissue microenvironment.
Dependencies are inferred from the claim text.